01968nas a2200361   4500000000100000008004100001260001300042653001500055653001000070653000900080653001600089653004300105653003300148653003000181653001100211653001100222653002300233653001200256653001000268653000900278653001600287653001800303653001300321100001500334700001600349700001400365700001600379245009000395300000900485490000700494520109100501022001401592       1985                            d  c1985 Mar10aAdolescent10aAdult10aAged10aBody Weight10aChemical and Drug Induced Liver Injury10aDrug Administration Schedule10aDrug Therapy, Combination10aFemale10aHumans10aIsonicotinic Acids10aleprosy10aLiver10aMale10aMiddle Aged10aProthionamide10aRifampin1 aCartel J L1 aNaudillon Y1 aArtus J C1 aGrosset J H00aHepatotoxicity of the daily combination of 5 mg/kg prothionamide + 10 mg/kg rifampin.  a15-80 v533 a<p>Because a 13% incidence of hepatotoxicity was observed in a first study of multibacillary leprosy patients treated daily with dapsone, rifampin, and 10 mg/kg thioamide, the patients were treated in a second study with 5 mg/kg thioamide in daily combination with dapsone and rifampin. In this study, monthly assessments of liver function were performed in order to detect early hepatic disturbances. Despite the reduced dosage of thioamide, a 16.5% incidence of hepatotoxicity was observed among 110 multibacillary patients. However, jaundice was observed in only 2 out of 18 cases of hepatotoxicity (11%); whereas it was observed in 5 out of the 7 cases of hepatotoxicity (71%) in the first study (p less than 0.05). The decrease in the thioamide dosage and the performance of monthly assessments of liver function did not decrease the incidence of hepatotoxicity but did decrease its severity. It is concluded that thioamide should not be used in daily combination with rifampin unless the daily dose is 5 mg/kg and monthly assessments of liver function are routinely performed.</p>  a0148-916X